News

Anti-microbial resistance surveillance creates publicly accessible records that identify emerging trends in AMR and inform policy to prevent it.

Long-acting cabotegravir plus rilpivirine worked with or without a lead-in for ART-naïve HIV patients.

Social factors, such as stigma or support, strongly impacted adolescent girls and young women deciding to use HIV PrEP in Kenya and South Africa.

A multicenter, randomized trial of patients in Europe and India showed improvements in mortality among patients with COVID-19 who received a higher dose of dexamethasone.

COVID-19 testing has been an integral part of our country’s strategy to limit disease transmission. Here’s the latest information on types of tests, when they’re appropriate to use, and what they realistically can and cannot do to curb infection.

Pfizer-BioNTech's request for the Emergency Use Authorization (EUA) will apply to everyone 18 years and older.

Antimicrobial resistance is a growing problem that requires international collaboration to educate the general public and stakeholders, while simultaneously developing solutions.

A new study looks at this population and what factors affect outcomes, including diagnosis. This is significant not only for pandemic response, but also preparedness for vulnerable patient populations.

Highlights from the sessions of the World Anti-Microbial Resistance Congress 2021 included addressing the global threat for AMR and looking at real world data and real world evidence to deter resistance.

The therapy can be used for the treatment of invasive candidiasis.

This morning, Regeneron released their phase 3 trail data for REGEN-COV, showing 4 injections provide up to 81.6% protection against symptomatic COVID-19.

A survey published in JAMA reveals some remain firmly entrenched.

People with rheumatologic conditions are more likely to experience COVID-19 symptoms lasting longer than a month, and this is affected by smoking or preexisting conditions.

Presentation highlights from the second and final day of the 9th Annual International C. diff Conference & Health Expo.

Interim, unpublished data show PAXLOVID is associated with 89% reductions in risk of COVID-19 hospitalization or death. Pfizer is now seeking FDA emergency authorization.

Dr. Tamás Haidegger talks about his work to develop an AI-based scanner that tracks hand hygiene to prevent C difficile and other infections.

Highlights from some of this afternoon's presenters at the 9th Annual International C diff Conference & Health Expo.

Highlights from the morning session of the C Diff Foundation Conference included data about Pfizer's investigational vaccine, insights about Seres Therapeutics microbiome therapeutic, and a look at CDI incidence rates around COVID-19.

Curtis Donskey, MD, discussed his efforts to encourage C. diff patients and providers to do their part to reduce infection and reinoculation.

The Biden administration is also setting mandates for health care workers in facilities receiving federal aid.

The investigational oral antiviral therapy from Merck is still awaiting FDA authorization.

The development of these programs are being looked at for private practices in the community settings to try to create better prescribing practices and avoid the potential progression to health care associated infections.

The CDC’s Advisory Committee on Immunization Practices voted to recommend hepatitis B, orthopoxviruses, and Ebola vaccines to certain populations, as well as approving 2022 immunization schedules for children, adolescents, and adults.

The organization is hosting its 9th Annual International C Diff Conference and Health EXPO on Thursday and Friday this week. The conference is virtual and free to the public.

Novavax was approved for their first COVID-19 vaccine EUA in Indonesia, and expects more to follow shortly.

In the latest article from SIDP, here is a look at the use of various intravenous (IV) antimicrobial therapies to address infections in these patients.

Suzan Walters, PhD, discusses her research on the PrEP care continuum among people who inject drugs in rural versus urban settings.

The ACIP considered the benefits of the newly emergency-authorized vaccine versus the risks of COVID-19 in children aged 5-11 years old.